• Principal Investigator
  • Male

Dr. B.J. Biemond

Position: Associate professor (UHD)
Main activities: Patient care, Research
Specialisation: Hematology
foto B.J. Biemond is one of the AMC Principal Investigators
Focus of research:

Sickle cell anemia

AMC themes: Infection & Immunity, Oncology
Departments: Internal Medicine: Clinical Haematology
Boshuizen M, van der Ploeg K, von Bonsdorff L, Biemond BJ, Zeerleder SS, van Bruggen R, Juffermans NP, Therapeutic use of transferrin to modulate anemia and conditions of iron toxicity. BLOOD REV 2017;31 (6):400-405 [PubMed]
Klaassen ILM, Lauw MN, van de Wetering MD, Biemond BJ, Middeldorp S, Abbink FCH, Bierings M, te Loo DMMW, Pieters R, van der Sluis IM, Tissing WJE, Zwaan CM, van Ommen CH, TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial. BMC PEDIATR 2017;17:122 [PubMed]
Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MCJC, Kuball J, Kooy MVM, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJM, Manz MG, Ossenkoppele GJ, Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. BLOOD 2017;129 (12):1636-1645 [PubMed]
Meinderts SM, Sins JWR, Fijnvandraat K, Nagelkerke SQ, Geissler J, Tanck MW, Bruggeman C, Biemond BJ, Rijneveld AW, Kerkhoffs JLH, Pakdaman S, Habibi A, van Bruggen R, Kuijpers TW, Pirenne F, van den Berg TK, Non-classical FCGR2C haplotype is associated with protection from red blood cell allo-immunization in sickle cell disease. BLOOD 2017;ahead of print [PubMed]
Schimmel M. Sickle cell disease: Pathogenesis and biomarkers. S.l.: s.n.; 2017. 205p. ISBN 9789492683441 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Brandjes DPM; copromotor(s): van Oers MHJ, Biemond BJ, Zeerleder SS)
Schimmel M, Luken BM, Nur E, van Tuijn CFJ, Sins JW, Brandjes DPM, Zeerleder SS, Biemond BJ, Inflammatory and endothelial markers during vaso-occlusive crisis and acute chest syndrome in sickle cell disease. AM J HEMATOL 2017;92 (11):E634-E636 [PubMed]
Sins JWR. Therapeutic targets in sickle cell disease. S.l.: s.n.; 2017. 283p. ISBN 978-94-92683-96-0 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Fijnvandraat CJ, van Oers MHJ; copromotor(s): Biemond BJ, Kuijpers TW)
Sins JWR, Fijnvandraat K, Rijneveld AW, Boom MB, Kerkhoffs JLH, van Meurs AH, de Groot MR, Heijboer H, Dresse MF, Lê PQ, Hermans P, Vanderfaeillie A, van den Neste EW, Benghiat FS, Kesse-Adu R, Delannoy A, Efira A, Azerad MA, de Borgie CA, Biemond BJ, Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial. BRIT J HAEMATOL 2017;ahead of print [PubMed]
Sins JWR, Schimmel M, Luken BM, Nur E, Zeerleder SS, van Tuijn CFJ, Brandjes DPM, Kopatz WF, Urbanus RT, Meijers JCM, Biemond BJ, Fijnvandraat K, Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state. J THROMB HAEMOST 2017;15 (7):1392-1402 [PubMed]
van de Weerdt EK, Biemond BJ, Baake B, Vermin B, Binnekade JM, van Lienden KP, Vlaar APJ, Central venous catheter placement in coagulopathic patients: risk factors and incidence of bleeding complications. TRANSFUSION 2017;57 (10):2512-2525 [PubMed]
van de Weerdt EK, Peters AL, Goudswaard EJ, Binnekade JM, van Lienden KP, Biemond BJ, Vlaar APJ, The practice of platelet transfusion prior to central venous catheterization in presence of coagulopathy: a national survey among clinicians. VOX SANG 2017;112 (4):343-351 [PubMed]
van Tuijn CFJ, Schimmel M, van Beers EJ, Nur E, Biemond BJ, Prospective evaluation of chronic organ damage in adult sickle cell patients: A seven-year follow-up study. AM J HEMATOL 2017;92 (10):E584-E590 [PubMed]
van Tuijn CFJ, Sins JWR, Fijnvandraat K, Biemond BJ, Daily pain in adults with sickle cell disease-a different perspective. AM J HEMATOL 2017;92 (2):179-186 [PubMed]
Versluis J, In 't Hout FEM, Devillier R, van Putten WLJ, Manz MG, Vekemans MC, Legdeur MC, Passweg JR, Maertens J, Kuball J, Biemond BJ, Valk PJM, van der Reijden BA, Meloni G, Schouten HC, Vellenga E, Pabst T, Willemze R, Löwenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen JJ, Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. LEUKEMIA 2017;31 (1):26-33 [PubMed]
Vlijm-Kievit A, Jorna NGE, Moll E, Pajkrt E, Pals ST, Middeldorp S, Biemond BJ, Zeerleder SS, Tio MA, Kemper EM, Hazenberg MD, Acute lymphoblastic leukemia during the third trimester of pregnancy. LEUKEMIA LYMPHOMA 2017;ahead of print [PubMed]
de Swart L, Hendriks JCM, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, Brittenham GM, Furman Y, Wojczyk B, Janssen MCH, Porter JB, Mattijssen VEJM, Biemond BJ, MacKenzie MA, Origa R, Galanello R, Hider RC, Swinkels DW, Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. HAEMATOLOGICA 2016;101 (1):38-45 [PubMed]
Schimmel M, Nur E, Mairuhu W, Brandjes DPM, Olde Engberink RHG, Vogt L, Biemond BJ, Urinary zinc loss in sickle cell disease primarily due to increased bone degradation. AM J HEMATOL 2016;91 (6):E311-E312 [PubMed]
Sins JWR, Biemond BJ, van den Bersselaar SM, Heijboer H, Rijneveld AW, Cnossen MH, Kerkhoffs JLH, van Meurs AH, von Ronnen FB, Zalpuri S, de Rijke YB, Ellen van der Schoot C, de Haas M, van der Bom JG, Fijnvandraat K, Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. AM J HEMATOL 2016;91 (8):763-769 [PubMed]
Slot LM, Hoogeboom R, Smit LA, Wormhoudt TAM, Biemond BJ, Oud MECM, Schilder-Tol EJM, Mulder AB, Jongejan A, van Kampen AHC, Kluin PM, Guikema JEJ, Bende RJ, van Noesel CJM, B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains. AM J PATHOL 2016;186 (12):3273-3284 [PubMed]
Cornelissen JJ, Versluis J, Passweg JR, van Putten WLJ, Manz MG, Maertens J, Beverloo HB, Valk PJM, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJWM, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B, Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. LEUKEMIA 2015;29 (5):1041-1050 [PubMed]
Lauw MN. Hypercoagulability in hematological malignancies. S.l.: s.n.; 2015. 293p. ISBN 978-94-6169-709-7 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Middeldorp S, van Oers MHJ; copromotor(s): Biemond BJ)
Montgomery M, van Santen MM, Biemond BJ, Diamond RH, Pals ST, Hepatosplenic T-Cell Lymphoma: A Population-Based Study Assessing Incidence and Association With Immune-Mediated Disease. GASTROENTEROL HEPATOL (N Y) 2015;11 (3):160-163 [PubMed]
Schimmel M, van Beers EJ, van Tuijn CFJ, Nur E, Rijneveld AW, Mac Gillavry MR, Brandjes DPB, Schnog JJB, Biemond BJ, N-terminal pro-B-type natriuretic peptide, tricuspid jet flow velocity, and death in adults with sickle cell disease. AM J HEMATOL 2015;90 (4):E75-E76 [PubMed]
van der Land V, Zwanenburg JJM, Fijnvandraat K, Biemond BJ, Hendrikse J, Mutsaerts HJMM, Visser F, Wardlaw JM, Nederveen AJ, Majoie CBLM, Nederkoorn PJ, Cerebral lesions on 7 tesla MRI in patients with sickle cell anemia. CEREBROVASC DIS 2015;39 (3-4):181-189 [PubMed]
Versluis J, Hazenberg CLE, Passweg JR, van Putten WLJ, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ [Contributors: Meulendijks I, Cornelisse P, van Hooije C, Biaggi C, van der Holt B, Labopin M, de Bock B, Breems DA, Zachee P, Ferrant A, Vekemans MC, Mineur P, Delannoy A, Maertens J, Verhoef G, van Steenweghen S, Bosly A, Graux C, Jaeger E, Theobald M, Beck J, Fischer T, Gjertsen BT, Bargetzi M, Wernli M, Passweg J, Gratwohl A, Leoncini-Francini L, Marini G, Fey MF, Pabst T, Chapuis B, Chalandon Y, Herr A, Wuillemin WA, Gregor M, Piquet D, Zimmerli-Schwab B, Hess U, Binder D, Kroner T, Mantz M, Jacky E, Schanz U, Wittebol S, van der Lelie J, Biemond BJ, Leeksma OC, Janssen JJWM, Ossenkoppele GJ, Huijgens PC, Deenik W, Posthuma W, Wijermans PW, Schaafsma MR, Legdeur M, Huls G, Vellenga E, Daenen SMGJ, Voogt PJ, Joosten P, Schouten HC, Laterveen L, Biesma DH, de Weerdt O, Löwenberg B, Cornelissen JJ, Sonneveld P, Zijlmans J, Jongen-Lavrencic M, de Greef GE, van Zaanen H, Verdonck LF, Kuball J, van Marwijk Kooy M]] , Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. LANCET HAEMATOL 2015;2 (10):e427-e436 [PubMed]
Wessel H, Wiersinga WJ, Biemond BJ, Goorhuis A, Baars PA, Krediet CTP, The best fit: do not discard AL amyloidosis too easily. ACTA CLIN BELG 2015;70 (1):73-75 [PubMed]
Zuurbier SM, Lauw MN, Coutinho JM, Majoie CBLM, van der Holt B, Cornelissen JJ, Middeldorp S, Biemond BJ, Stam J, Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia. J STROKE CEREBROVASC 2015;24 (7):1679-1684 [PubMed]
Zwaginga JJ, van der Holt B, te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HFM, Novotny VMJ, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus ECM, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JAC, Schrama JG, Valster FAA, Velders GA, Koene HR, Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. HAEMATOLOGICA 2015;100 (3):e90-e92 [PubMed]
van Beers EJ, van der Plas MN, Nur E, Bogaard HJ, van Steenwijk RP, Biemond BJ, Bresser P, Exercise tolerance, lung function abnormalities, anemia, and cardiothoracic ratio in sickle cell patients. AM J HEMATOL 2014;89 (8):819-824 [PubMed]
Jansen RR, Biemond BJ, Schinkel J, Koekkoek SM, Molenkamp R, de Jong MD, Visser CE, Febrile neutropenia: significance of elaborated screening for respiratory viruses, and the comparison of different sampling methods, in neutropenic patients with hematological malignancies. VIROL J 2013;10 (1):212 [PubMed]
Lauw MN, van der Holt B, Middeldorp S, Meijers JCM, Cornelissen JJ, Biemond BJ, Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation. THROMB HAEMOSTASIS 2013;109 (4):633-642 [PubMed]
Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A [Contributors: Chong B, Pidcock M, Pabinger-Fasching I, Olney H, Arnold D, Assouline S, Shen Z, Yang R, Sun A, Mayer J, Pohlreichova V, Hlusi A, Marcher C, Nousiainen T, Godeau B, Cheze S, Viallard J, Ganser A, Matzdorff A, Salama A, Schroeder D, von Depka Prondzinski M, Hiller E, Rummel M, Anagnostopoulos A, Poziopoulos C, Wong R, Fabris F, Ciceri F, Angelini F, Vianelli N, Kim B, Novotný V, Biemond BJ, Schipperus MR, Wittebol S, Blacklock H, Simpson D, Ganly P, Doocey R, Shamsi T, Aziz Z, Murillo S, Ulloa V, Kloczko J, Dmoszynska A, Robak T, Kuliczkowski K, Homenda W, Calbecka M, Antonio Stoia R, Vladareanu A, Kovaleva L, Rukavitsyn O, Domnikova N, Abdulkadyrov K, Palasthy S, Reimana JA, Lazur J, Escudero Soto A, Besalduch J, Páramo Fernández J, Gerosa S, Ribera Santasusana J, Perez Crespo S, Alonso A, Pascual Izquierdo C, Wadenvik H, Lerner R, Tsay W, Rojnuckarin P, Sirijerachai C, Meddeb B, M'Sadek F, Khelif A, Davies S, Nokes T, Grech H, Al-Ismail S, Scully M, Martlew V, Masliak Z, Kaplan P, Cosgriff T, Giudice R, Hon J, Kuriakose P, Liebman H, Flynn P, Smith D, Fogarty P, Quick D, de Oliveira M, Taylor M, Gernsheimer T, Pullarkat V, Rarick M, Scroggin C Jr, George J, Soong Ahn Y, Kuter D, Tarantino M, McCrae K, Phan L]] , Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. BLOOD 2013;121 (3):537-545 [PubMed]
Schimmel M, Nur E, Biemond BJ, van Mierlo GJ, Solati S, Brandjes DP, Otten HM, Schnog JJ, Zeerleder S, Nucleosomes and neutrophil activation in sickle cell disease painful crisis. HAEMATOLOGICA 2013;98 (11):1797-1803 [PubMed]
Terwijn M, van Putten WLJ, Kelder A, van der Velden VHJ, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJM, Preijers FWMB, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJM, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ, High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. J CLIN ONCOL 2013;31 (31):3889-+ [PubMed]
Thielen N, van der Holt B, Cornelissen JJ, Verhoef GEG, Gussinklo T, Biemond BJ, Daenen SMG, Deenik W, van Marwijk Kooy R, Petersen E, Smit WM, Valk PJM, Ossenkoppele GJ, Janssen JJWM, Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). EUR J CANCER 2013;49 (15):3242-3246 [PubMed]
Tonino SH, Nur E, Otten HM, Wykrzykowska JJ, Hoekstra JBL, Biemond BJ, Chest pain in sickle cell disease. NETH J MED 2013;71 (5):265-269 [PubMed]
van der Land V, Peters M, Biemond BJ, Heijboer H, Harteveld CL, Fijnvandraat K, Markers of endothelial dysfunction differ between subphenotypes in children with sickle cell disease. THROMB RES 2013;132 (6):712-717 [PubMed]
Yürük K, Milstein DMJ, Bezemer R, Bartels SA, Biemond BJ, Ince C, Transfusion of banked red blood cells and the effects on hemorrheology and microvascular hemodynamics in anemic hematology outpatients. TRANSFUSION 2013;53 (6):1346-1352 [PubMed]
Daenen S, van der Holt B, Dekker AW, Willemze R, Rijneveld AW, Biemond BJ, Muus P, van de Loosdrecht AA, Schouten HC, van Marwijk Kooy M, Breems DA, Demuynck H, Maertens J, Wijermans PW, Wittebol S, de Klerk EW, Cornelissen JJ, Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. LEUKEMIA 2012;26 (7):1726-1729 [PubMed]
Lammers AJJ, de Porto APNA, Bennink RJ, van Leeuwen EMM, Biemond BJ, Goslings JC, van Marle J, ten Berge IJM, Speelman P, Hoekstra JBL, Hyposplenism: Comparison of different methods for determining splenic function. AM J HEMATOL 2012;87 (5):484-489 [PubMed]
Lauw MN, Bus EWN, van Wulfften Palthe AFY, Coppens M, Homburg CH, Middeldorp S, van der Schoot CE, Koene HR, Biemond BJ, Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg. ANN HEMATOL 2012;91 (1):103-107 [PubMed]
Metske HA, Postema PG, Biemond BJ, Bouman CSC, Cooling the crisis: Therapeutic hypothermia after sickle cardiac arrest. CRIT CARE MED 2012;40 (2):651-653 [PubMed]
Nur E, Brandjes DP, Teerlink T, Otten HM, Oude Elferink RPJ, Muskiet F, Evers LM, ten Cate H, Biemond BJ, Duits AJ, Schnog JJB, N-acetylcysteine reduces oxidative stress in sickle cell patients. ANN HEMATOL 2012;91 (7):1097-1105 [PubMed]
Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJM, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GEG, de Weerdt O, Wijermans P, Passweg JR, Löwenberg B, Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). BLOOD 2012;120 (24):4706-4711 [PubMed]
van der Laan AM, Hirsch A, Robbers LFHJ, Nijveldt R, Lommerse I, Delewi R, van der Vleuten PA, Biemond BJ, Zwaginga JJ, van der Giessen WJ, Zijlstra F, van Rossum AC, Voermans C, van der Schoot CE, Piek JJ, A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: Monocytes and myocardial infarction. AM HEART J 2012;163 (1):57-65 [PubMed]
Yuruk K, Bartels SA, Milstein DMJ, Bezemer R, Biemond BJ, Ince C, Red blood cell transfusions and tissue oxygenation in anemic hematology outpatients. TRANSFUSION 2012;52 (3):641-646 [PubMed]
Hazenberg MD, Biemond BJ, Pals ST, Zumpolle CM, Schinkel CJ, Linthorst GE, Hoekstra JBL, Vos JMI, Clinical pathological conference: a non-Hodgkin's lymphoma patient with persistent anaemia after chemotherapy. NETH J MED 2011;69 (10):469-473 [PubMed]
Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JGP, van der Giessen WJ, Tio RA, Waltenberger J, ten Berg JM, Doevendans PA, Aengevaeren WRM, Zwaginga JJ, Biemond BJ, van Rossum AC, Piek JJ, Zijlstra F, Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. EUR HEART J 2011;32 (14):1736-1747 [PubMed]
Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ [Contributors: Ferrant A, Delannoy A, Mineur P, Maertens J, Verhoef G, Demuynck H, Bosly A, Graux C, Breems DA, Zachee P, Jaeger E, Theobald M, Beck J, Fischer T, Bargetzi M, Wernli M, Gratwohl A, Heim D, Fey MF, Pabst T, Chapuis B, Herr A, Wuillemin WA, Gregor M, Jacky E, Schans U, Wittebol S, van der Lelie J, Biemond BJ, de Valk B, Ossenkoppele GJ, Huijgens PC, Wijermans PW, Schaafsma MR, Legdeur M, Daenen SMGJ, Vellenga E, Voogt PJ, Schouten HC, Biesma DH, Sonneveld P, Zijlmans J, de Greef GE, Löwenberg B, Verdonck LF, Kuball J, van Marwijk Kooy M]] , Cytarabine dose for acute myeloid leukemia. NEW ENGL J MED 2011;364 (11):1027-1036 [PubMed]
Nur E. Vasculopathy in sickle cell disease. s.l.: s.n.; 2011. 211p. ISBN 9789090260877 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ; copromotor(s): Biemond BJ, Brandjes DPM)
Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJB, Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. AM J HEMATOL 2011;86 (6):484-489 [PubMed]
Nur E, van Beers EJ, Martina S, Cuccovillo I, Otten HM, Schnog JJB, Meijers JCM, Mantovani A, Brandjes DP, Bottazzi B, Biemond BJ, Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. BLOOD CELL MOL DIS 2011;46 (3):189-194 [PubMed]
Nur E, Verwijs M, de Waart DR, Schnog JJB, Otten HM, Brandjes DP, Biemond BJ, Elferink RPJO, Increased efflux of oxidized glutathione (GSSG) causes glutathione depletion and potentially diminishes antioxidant defense in sickle erythrocytes. BBA-MOL BASIS DIS 2011;1812 (11):1412-1417 [PubMed]
Rijneveld AW, van der Holt B, Daenen SMGJ, Biemond BJ, de Weerdt O, Muus P, Maertens J, Mattijssen V, Demuynck H, Legdeur MCJC, Wijermans PW, Wittebol S, Spoelstra FM, Dekker AW, Ossenkoppele GJ, Willemze R, Cornelissen JJ, Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. LEUKEMIA 2011;25 (11):1697-1703 [PubMed]
van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KSG, van de Loosdrecht AA, Koedam J, Veeger NJGM, Vellenga E, Huls G, Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. BRIT J HAEMATOL 2011;155 (5):599-606 [PubMed]
van der Laan AM, Hirsch A, Haeck JDE, Nijveldt R, Delewi R, Biemond BJ, Tijssen JGP, Marques KMJ, Zijlstra F, van Rossum AC, Piek JJ, Recovery of microcirculation after intracoronary infusion of bone marrow mononuclear cells or peripheral blood mononuclear cells in patients treated by primary percutaneous coronary intervention the Doppler substudy of the Hebe trial. JACC-CARDIOVASC INTE 2011;4 (8):913-920 [PubMed]
van der Plas EM, van den Tweel XW, Geskus RB, Heijboer H, Biemond BJ, Peters M, Fijnvandraat K, Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening. BRIT J HAEMATOL 2011;155 (1):106-110 [PubMed]
Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF, Löwenberg B [Contributors: Ferrant A, Delannoy A, Maertens J, Verhoef G, Bosly A, Graux C, Breems DA, Zachee P, Mineur P, Jaeger E, Theobald M, Beck J, Fischer T, Bargetzi M, Wernli M, Gratwohl A, Fey MF, Pabst T, Chapuis B, Chalandon Y, Herr A, Wuillemin WA, Gregor M, Jacky E, Schanz U, Leoncini-Francini L, Marini G, Piquet D, Zimmerli-Schwab B, Hess U, Binder D, Kroner T, Wittebol S, van der Lelie J, Biemond BJ, Leeksma OC, Ossenkoppele GJ, Huijgens PC, Soesan M, Wijermans PW, Schaafsma MR, Legdeur M, Vellenga E, Daenen SMGJ, Voogt PJ, Schouten HC, Biesma DH, de Weerdt O, Löwenberg B, Cornelissen JJ, Sonneveld P, Zijlmans J, Jongen-Lavrencic M, de Greef GE, Verdonck LF, Kuball J, van Marwijk Kooy M]] , Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. BLOOD 2011;118 (23):6037-6042 [PubMed]
Biemond BJ, Endoscopic ultrasonography and pancreatic cancer - close companions. NETH J MED 2010;68 (9):341-342 [PubMed]
Biemond BJ, Treatment considerations for primary myelofibrosis. NETH J MED 2010;68 (1):291-292 [PubMed]
Kaandorp SP, Lauw MN, van der Schoot CE, Goddijn M, van der Veen F, Koene HR, Biemond BJ, Middeldorp S, Prevalence of JAK2V617F mutation in women with unexplained recurrent miscarriage. J THROMB HAEMOST 2010;8 (12):2837-2839 [PubMed]
Landburg PP, Teerlink T, Biemond BJ, Brandjes DPM, Muskiet FAJ, Duits AJ, Schnog JB, Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. BLOOD CELL MOL DIS 2010;44 (4):229-232 [PubMed]
Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Döhner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J [Contributors: Ferrant A, Delannoy A, Maertens J, Verhoef G, Demuynck H, Bosly A, Graux C, Breems DA, Zachee P, Jaeger E, Beck J, Fischer T, von Lilienfeld-Toal M, Glasmacher A, Hartmann F, Grimminger W, Döhner H, Bargetzi M, Wernli M, Gratwohl A, Fey MF, Pabst T, Passweg J, Chalandon Y, Herr A, Wuillemin WA, Stuessi G, Schanz U, van der Lelie J, Biemond BJ, de Valk B, Ossenkoppele GJ, Huijgens PC, Wijermans PW, Levin MD, Schaafsma MR, Daenen SMGJ, Vellenga E, Voogt PJ, Schouten HC, Biesma DH, Sonneveld P, Zijlmans J, Jongen-Lavrencic M, de Greef GE, Löwenberg B, Verdonck LF, Kuball J, van Marwijk Kooy M, Milligan DW, Pocock C, Aldouri M]] , Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. BLOOD 2010;115 (13):2586-2591 [PubMed]
Milstein DMJ, te Boome LCJ, Cheung YW, Lindeboom JAH, van den Akker HP, Biemond BJ, Ince C, Use of sidestream dark-field (SDF) imaging for assessing the effects of high-dose melphalan and autologous stem cell transplantation on oral mucosal microcirculation in myeloma patients. ORAL SURG ORAL MED O 2010;109 (1):91-97 [PubMed]
Nur E, Brandjes DP, Schnog JJB, Otten HM, Fijnvandraat K, Schalkwijk CG, Biemond BJ, Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients. BRIT J HAEMATOL 2010;151 (1):62-69 [PubMed]
Nur E, Mairuhu W, Biemond BJ, van Zanten AP, Schnog JJB, Brandjes DP, Otten HM, Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis. AM J HEMATOL 2010;85 (11):902-904 [PubMed]
van Beers EJ, Biemond BJ, Schnog JJB, Letter in response to: "Pulmonary thrombi are not detected by 3D magnetic resonance angiography in adults with sickle cell anemia and an elevated triscuspid regurgitant jet velocity". AM J HEMATOL 2010;85 (3):217 [PubMed]
Van der Plas EM, van den Tweel XW, Heijboer H, Geskus RB, Biemond BJ, Peters M, Fijnvandraat K, Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening.. PEDIATR CLIN AMSTERDAM 2010;21 (1):5-6
van Tuijn CFJ, Nur E, van Beers EJ, Zaaijer HL, Biemond BJ, Acute chest syndrome in sickle cell disease due to the new influenza A (H1N1) virus infection. AM J HEMATOL 2010;85 (4):303-304 [PubMed]
van Tuijn CFJ, van Beers EJ, Schnog JJB, Biemond BJ, Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. AM J HEMATOL 2010;85 (7):532-535 [PubMed]
Biemond BJ, Preventie en behandeling van sikkelcelziektegerelateerde complicaties. NED TIJDSCHR HEMATOL 2009;6 (2):56-61
Biemond BJ, Kerkhoffs JLH, Indicaties voor bloedtransfusie bij sikkelcelziekte. TIJDSCHR BLOEDTRANSFUSIE 2009;2 (4):118-124
de Heer K, Visser CE, Biemond BJ, Blijlevens NMA, De plaats van primaire antimycotische profylaxe bij intensieve chemotherapie en allogene stamceltransplantatie. NED TIJDSCHR HEMATOL 2009;6 (7):268-275
Kerkhoffs JLH, Smiers FJ, Biemond BJ, Overwegingen en dilemma's rond allogene stamceltransplantatie voor sikkelcelziekte. NED TIJDSCHR HEMATOL 2009;6 (5):173-181
Kim YS, Nur E, van Beers EJ, Truijen J, Davis SCAT, Biemond BJ, van Lieshout JJ, Dynamic Cerebral Autoregulation in Homozygous Sickle Cell Disease. STROKE 2009;40 (3):808-814 [PubMed]
Kroot JJC, Laarakkers CMM, Kemna EHJM, Biemond BJ, Swinkels DW, Regulation of serum hepcidin levels in sickle cell disease. HAEMATOLOGICA 2009;94 (6):885-887 [PubMed]
Landburg PP, Nur E, Maria N, Brandjes DPM, Biemond BJ, Schnog JB, Duits AJ, Elevated circulating stromal-derived factor-1 levels in sickle cell disease. ACTA HAEMATOL-BASEL 2009;122 (1):64-69 [PubMed]
Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G [Contributors: Ferrant A, Delannoy A, Maertens J, Verhoef G, Demuynck H, Bosly A, Graux C, Breems DA, Zachee P, Jaeger E, Beck J, Fischer T, von Lilienfeld-Toal M, Glasmacher A, Salwender HJ, Hartmann F, Goetze K, Grimminger W, Döhner H, Bargetzi M, Wernli M, Gratwohl A, Fey MF, Pabst T, Chapuis B, Herr A, Wuillemin WA, Jacky E, Schans U, Wittebol S, van der Lelie J, Biemond BJ, de Valk B, Ossenkoppele GJ, Huijgens PC, Wijermans PW, Levin MD, Schaafsma MR, Daenen SMGJ, Vellenga E, Voogt PJ, Schouten HC, Biesma DH, Sonneveld P, Zijlmans J, Jongen-Lavrencic M, de Greef GE, Löwenberg B, Verdonck LF, Kuball J, van Marwijk Kooy M, Milne A, Milligan DW, Pocock C, Burnett AK, Aldouri M, Dennis M]] , High-dose daunorubicin in older patients with acute myeloid leukemia. NEW ENGL J MED 2009;361 (13):1235-1248 [PubMed]
Nur E, Kim YS, Truijen J, van Beers EJ, Davis SCAT, Brandjes DP, Biemond BJ, van Lieshout JJ, Cerebrovascular reserve capacity is impaired in patients with sickle cell disease. BLOOD 2009;114 (16):3473-3478 [PubMed]
Strijbos MH, Landburg PP, Nur E, Teerlink T, Leebeek FWG, Rijneveld AW, Biemond BJ, Sleijfer S, Gratama JW, Duits AJ, Schnog JJB, Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia?. BLOOD CELL MOL DIS 2009;43 (1):63-67 [PubMed]
Takkenberg RB, Zaaijer HL, ten Cate DF, Biemond BJ, Jansen PLM, Reesink HW, Reactivatie van het hepatitis B-virus bij patiënten met een hematologische maligniteit. NED TIJDSCHR GENEESKD 2009;153 (19):926-931 [PubMed]
van Beem RT, Nur E, Zwaginga JJ, Landburg PP, van Beers EJ, Duits AJ, Brandjes DP, Lommerse I, de Boer HC, van der Schoot CE, Schnog JJB, Biemond BJ, Elevated endothelial progenitor cells during painful sickle cell crisis. EXP HEMATOL 2009;37 (9):1054-1059 [PubMed]
van Beers EJ, Schaap MCL, Berckmans RJ, Nieuwland R, Sturk A, van Doormaal FF, Meijers JCM, Biemond BJ, Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. HAEMATOLOGICA 2009;94 (11):1513-1519 [PubMed]
van Beers E, Schnog JJ, Biemond B, Lung function tests in patients with sickle cell disease: A reply. AM J HEMATOL 2009;84 (5):310-311 [PubMed]
Biemond BJ, Giordano PC. Hemoglobinopathieën: abnormale hemoglobines en thalassemieën - hoofdstuk 6 in: Löwenberg B, Ossenkoppele GJ, editors. Handboek Hematologie. Utrecht: De Tijdstroom; 2008., p. 65-80
Hirsch A, Nijveldt R, van der Vleuten PA, Tio RA, van der Giessen WJ, Marques KMJ, Doevendans PA, Waltenberger J, ten Berg JM, Aengevaeren WRM, Biemond BJ, Tijssen JGP, van Rossum AC, Piek JJ, Zijlstra F, Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: Pilot study of the multicenter HEBE trial. CATHETER CARDIO INTE 2008;71 (3):273-281 [PubMed]
Landburg PP, Teerlink T, van Beers EJ, Muskiet FAJ, Kappers-Klunne MC, van Esser JWJ, Mac Gillavry MR, Biemond BJ, Brandjes DPM, Duits AJ, Schnog JJ, Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension. HAEMATOLOGICA 2008;93 (9):1410-1412 [PubMed]
van Beem RT, Hirsch A, Lommerse IM, Zwaginga JJ, Noort WA, Biemond BJ, Piek JJ, van der Schoot CE, Voermans C, Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarction. EUROINTERVENTION 2008;4 (1):133-138 [PubMed]
van Beers EJ. Sickle cell disease, pathophysiology and clinical complications.. s.l.: s.n.; 2008. 187p. ISBN 9789090233994 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ; copromotor(s): Biemond BJ, Schnog JB)
van Beers EJ, Goedhart PT, Unger M, Biemond BJ, Ince C, Normal sublingual microcirculation during painful crisis in sickle cell disease. MICROVASC RES 2008;76 (1):57-60 [PubMed]
van Beers EJ, Nieuwdorp M, Duits AJ, Evers LM, Schnog JJB, Biemond BJ, Sickle cell patients are characterized by a reduced glycocalyx volume. HAEMATOLOGICA 2008;93 (2):307-308 [PubMed]
van Beers EJ, Nur E, Schaefer-Prokop CM, Mac Gillavry MR, van Esser JWJ, Brandjes DPM, Kappers-Klunne MC, Duits AJ, Muskiet FAJ, Schnog JJB, Biemond BJ, Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. AM J HEMATOL 2008;83 (11):850-854 [PubMed]
van Beers EJ, Spronk HMH, ten Cate H, Duits AJ, Brandjes DPM, van Esser JWJ, Biemond BJ, Schnog JB, No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. HAEMATOLOGICA 2008;93 (5):e42-e44 [PubMed]
van Beers EJ, van Eck-Smit BLF, Mac Gillavry MR, van Tuijn CFJ, van Esser JWJ, Brandjes DPM, Kappers-Klunne MC, Duits AJ, Biemond BJ, Schnog JJB, Large and medium-sized pulmonary artery obstruction does not play a role of primary importance in the etiology of sickle-cell disease-associated pulmonary hypertension. CHEST 2008;133 (3):646-652 [PubMed]
van Beers EJ, van Tuijn CFJ, Mac Gillavry MR, van der Giessen A, Schnog JJB, Biemond BJ, Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. HAEMATOLOGICA 2008;93 (5):757-760 [PubMed]
van der Laan A, Hirsch A, Nijveldt R, van der Vleuten PA, van der Giessen WJ, Doevendans PA, Waltenberger J, ten Berg JM, Aengevaeren WRM, Zwaginga JJ, Biemond BJ, van Rossum AC, Tijssen JGP, Zijlstra F, Piek JJ, Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results. NETH HEART J 2008;16 (12):436-439 [PubMed]
Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, Buller HR, Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939) - an oral, direct factor Xa inhibitor. THROMB HAEMOSTASIS 2007;97 (3):471-477 [PubMed]
de Heer K, Silbermann MH, Koene HR, Biemond BJ, Muller HP, van Oers MHJ, Systematische diagnostiek van erytrocytose. NED TIJDSCHR GENEESKD 2007;151 (32):1770-1776 [PubMed]
Klein SK, Biemond BJ, van Oers MHJ, Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA). ANN HEMATOL 2007;86 (12):917-918 [PubMed]
Koene HR, Biemond BJ, van der Schoot CE, Van gen naar ziekte; JAK2 en polycythaemia vera. NED TIJDSCHR GENEESKD 2007;151 (32):1784-1787 [PubMed]
Niers TMH, Di Nisio M, Klerk CPW, Baarslag HJ, Bueller HR, Biemond BJ, Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J THROMB HAEMOST 2007;5 (9):1878-1882 [PubMed]
van Beers EJ, van Tuijn CFJ, Nieuwkerk PT, Friederich PW, Vranken JH, Biemond BJ, Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. AM J HEMATOL 2007;82 (11):955-960 [PubMed]
Hirsch A, Nijveldt R, van der Vleuten PA, Biemond BJ, Doevendans PA, van Rossum AC, Tijssen JG, Zijlstra F, Piek JJ, Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial--a prospective, multicenter, randomized trial. AM HEART J 2006;152 (3):434-441 [PubMed]
van Beers EJ, Peters M, Biemond BJ, Pathofysiologie en behandeling van sikkelcelziekte. NED TIJDSCHR GENEESKD 2005;149 (21):1144-1149 [PubMed]
van Royen N, Schirmer SH, Atasever B, Behrens CYH, Ubbink D, Buschmann EE, Voskuil M, Bot P, Hoefer I, Schlingemann RO, Biemond BJ, Tijssen JG, Bode C, Schaper W, Oskam J, Legemate DA, Piek JJ, Buschmann I, START trial - A pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. CIRCULATION 2005;112 (7):1040-1046 [PubMed]
ter Horst SAJ, Wagenaar GTM, de Boer E, van Gastelen MA, Meijers JCM, Biemond BJ, Poorthuis BJHM, Walther FJ, Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J APPL PHYSIOL 2004;97 (5):2014-2019 [PubMed]
Friederich PW, Keller TT, Biemond BJ, Peters RJ, Hornberger W, Büller HR, Levi M, Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor. THROMB HAEMOSTASIS 2000;84 (5):858-864 [PubMed]
Levi M, Friederich PW, Middleton S, de Groot PG, Wu YP, Harris R, Biemond BJ, Heijnen HF, Levin J, ten Cate JW, Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. NAT MED 1999;5 (1):107-111 [PubMed]
Levi M, van der Poll T, ten Cate H, Kuipers B, Biemond BJ, Jansen HM, ten Cate JW, Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. AM J RESP CRIT CARE 1998;158 (1):92-98 [PubMed]
Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H, Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J CLIN INVEST 1998;101 (1):10-14 [PubMed]
Biemond BJ, Friederich PW, Koschinsky ML, Levi M, Sangrar W, Xia J, Büller HR, ten Cate JW, Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. CIRCULATION 1997;96 (5):1612-1615 [PubMed]
Friederich PW, Levi M, Biemond BJ, Charlton P, Templeton D, van Zonneveld AJ, Bevan P, Pannekoek H, ten Cate JW, Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. CIRCULATION 1997;96 (3):916-921 [PubMed]
Biemond BJ, Friederich PW, Levi M, Vlasuk GP, Büller HR, ten Cate JW, Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. CIRCULATION 1996;93 (1):153-160 [PubMed]
ten Cate H, Biemond BJ, Levi M, Wuillemin WA, Bauer KA, Barzegar S, Buller HR, Hack CE, ten Cate JW, Rosenberg RD, Factor XIa induced activation of the intrinsic cascade in vivo. THROMB HAEMOSTASIS 1996;75 (3):445-449 [PubMed]
Wuillemin WA, Hack CE, Bleeker WK, Biemond BJ, Levi M, ten Cate H, Inactivation of factor Xia in vivo: studies in chimpanzees and in humans. THROMB HAEMOSTASIS 1996;76 (4):549-555 [PubMed]
Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H, Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. CIRCULATION 1995;91 (4):1175-1181 [PubMed]
Biemond BJ, Levi M, ten Cate H, Soule HR, Morris LD, Foster DL, Bogowitz CA, van der Poll T, Büller HR, ten Cate JW, Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. THROMB HAEMOSTASIS 1995;73 (2):223-230 [PubMed]
Biemond BJ, Levi M, ten Cate H, van der Poll T, Büller HR, Hack CE, ten Cate JW, Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. CLIN SCI 1995;88 (5):587-594 [PubMed]
van der Poll T, Levi M, ten Cate H, Jansen J, Biemond BJ, Haagmans BL, Eerenberg A, van Deventer SJ, Hack CE, ten Cate JW, Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees. CLIN EXP IMMUNOL 1995;100 (1):21-25 [PubMed]
Biemond BJ, Levi M, Nurmohamed MT, Büller HR, ten Cate JW, Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model. THROMB HAEMOSTASIS 1994;72 (3):377-380 [PubMed]
ten Cate H, Levi M, van der Poll T, Biemond BJ, van Deventer SJ, Buller HR, ten Cate JW, Inhibition of extrinsic coagulation activation in endotoxemia; therapeutic implications. PROG CLIN BIOL RES 1994;388:215-219 [PubMed]
ten Cate H, Schenk BE, Biemond BJ, Levi M, van der Poll T, Buller HR, ten Cate JW, A review of studies of the activation of the blood coagulation mechanism in chimpanzees (Pan troglodytes). J MED PRIMATOL 1994;23 (5):280-284 [PubMed]
van der Poll T, Levi M, van Deventer SJ, ten Cate H, Haagmans BL, Biemond BJ, Büller HR, Hack CE, ten Cate JW, Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. BLOOD 1994;83 (2):446-451 [PubMed]
Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H, Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. CIRCULATION 1992;85 (1):305-312 [PubMed]
Levi M, Biemond BJ, Stuck A, ten Cate JW, The effect of radiological contrast media in animal models of experimental thrombosis. SEMIN HEMATOL 1991;28 (4 Suppl 7):27-30; discussion 38-41 [PubMed]
Levi M, Biemond BJ, Sturk A, Hoek J, ten Cate JW, Variable effects of radiological contrast media on thrombus growth in a rabbit jugular vein thrombosis model. THROMB HAEMOSTASIS 1991;66 (2):218-221 [PubMed]
Key publications

Schimmel M, Nur E, Mairuhu W, Brandjes DPM, Olde Engberink RHG, Vogt L, Biemond BJ, Urinary zinc loss in sickle cell disease primarily due to increased bone degradation. AM J HEMATOL 2016;91 (6):E311-E312 [PubMed]
Schimmel M, van Beers EJ, van Tuijn CFJ, Nur E, Rijneveld AW, Mac Gillavry MR, Brandjes DPB, Schnog JJB, Biemond BJ, N-terminal pro-B-type natriuretic peptide, tricuspid jet flow velocity, and death in adults with sickle cell disease. AM J HEMATOL 2015;90 (4):E75-E76 [PubMed]
Nur E, van Beers EJ, Martina S, Cuccovillo I, Otten HM, Schnog JJB, Meijers JCM, Mantovani A, Brandjes DP, Bottazzi B, Biemond BJ, Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. BLOOD CELL MOL DIS 2011;46 (3):189-194 [PubMed]
Lauw MN, Bus EWN, van Wulfften Palthe AFY, Coppens M, Homburg CH, Middeldorp S, van der Schoot CE, Koene HR, Biemond BJ, Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg. ANN HEMATOL 2012;91 (1):103-107 [PubMed]
Lauw MN, van der Holt B, Middeldorp S, Meijers JCM, Cornelissen JJ, Biemond BJ, Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation. THROMB HAEMOSTASIS 2013;109 (4):633-642 [PubMed]


All Publications

Curriculum Vitae

Bart Biemond is working in the Academic Medical Center as senior staff member of the Department of Hematology and responsible for general hematological care and education (both benign and hemato-oncology). He has been working as an internist hematologist for 15 years and is involved in patient care, supervision of hematology fellows and residents. Furthermore, he is working as a consultant for hematology in the Flevo Hospital in Almere and the OLVG Hospital in Amsterdam. His focus of research is sickle cell disease and coagulopathy in patients with hematological malignancies. As a member of the CURAMA and Score study group he has focused on clinical and pre-clinical studies on vasculopathy in SCD. Moreover, he is active member of the acute leukemia and benign hematology working group of HOVON. 

 

Research programmes

Vasculopathy in sickle cell disease/Coagulopathy in hemotological malignancies

The coming 5 years research will focus on: 1. the value of specific biomarkers in SCD; 2. evaluation of the development of organ damage in SCD; and 3. performing intervention studies to test new therapies to prevent or treat vaso-occlusive crises.

Ad 1.
The biomarker studies will help to determine specific risk groups, but may also be helpful in the understanding of the pathogenesis of SCD. Specific biomarkers of interest are: nucleosomes, zinc and pentaxine-3. In a recent study nucleosomes have been demonstrated to play an important role in the inflammatory response in sickle cell disease crises. Future studies will aim at the source of these nucleosomes and the exact mechanism by which they are related to the inflammatory response and endothelial damage.

Ad 2.
Clinical studies will focus on specific complications of SCD. In particular, the prevention of acute chest syndrome (an often fatal complication of sickle cell diseas) by incentive spirometry and the detection of liver fibrosis due to recurrent vaso-occlusion will be the main target for the coming years. The value of spirometry will be tested prospectively and a large cross sectional study with the use of the Fibroscan will be performed to evaluate the increasing frequency of liver failure in relative young sickle cell patients for which no clear explanation could be found.

Ad 3.
Different intervention studies to test new therapeutic strategies are planned for the coming years. First, a multicentre study will start this year to study the effect of the antioxidant n-acetylcysteine on the prevention of sickle cell crises and daily pain. A smaller phase 2 intervention study will be performed to evaluate the effect of vitamin D suppletion on daily pain which may be caused by osteomalacia due to vitamin D deficiency which is very prevalent in SCD. Within a recently started European collaboration a large randomized controlled trial is currently being designed to assess the effect of a selective p-selectine inhibitor in the treatment of patients with a sickle cell crisis. The AMC will be the leading centre in this European collaboration.

Faculty
Dr. B.J. Biemond

PhD Students
C.F.J. van Tuijn BSc MSc
L. Václavů MSc
Drs. E.K. van de Weerdt

Others
Drs. I.L.M. Klaassen
Drs. E.K. van de Weerdt

Prof. dr. M.H.J. van Oers (Pathogenesis and Immunotherapy of B cell malignancies)

Other research related activities
  • Contribution to guidelines and protocols, Dutch guidelines for CML treatment
  • Contribution to guidelines and protocols, Dutch guidelines for Myeloproliferative neoplasms
  • Contribution to guidelines and protocols, Dutch guidelines for diagnosis and treatment of MDS
  • Membership of medical or scientific committee, HOVON, Board member
  • Contribution to guidelines and protocols, Dutch guidelines for sickle cell disease
  • Contribution to guidelines and protocols, Dutch guidelines for blood transfusion
Current research funding
  • Ergomed Clinical Research PLC
  • Karyopharm Therapeutics Inc.
  • Roche Nederland B.V.
  • Stichting Hovon Amsterdam, p/a VUmc
  • ZonMw